Additionally, future studies should investigate how these targets interact with known MM drivers, and whether combining an ORM1/OVGP1-targeted approach with existing therapies (like proteasome inhibitors or immunotherapies) yields synergistic benefits. Here, OVGP1 is linked to Miyoshi myopathy.